Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio Inc (ANVS) is a clinical-stage biopharmaceutical company advancing novel therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. This page aggregates all material announcements, regulatory filings, and research developments related to their drug pipeline.
Investors and researchers will find timely updates on clinical trial progress for lead candidate buntanetap, intellectual property milestones, and strategic collaborations. The curated news collection provides essential context for evaluating the company's scientific approach to targeting multiple neurotoxic proteins.
Key content includes updates on Phase III trial outcomes, FDA communications, partnership agreements with academic institutions, and financial reporting. All information is sourced from verified channels to ensure accuracy and compliance with disclosure standards.
Bookmark this page for streamlined tracking of ANVS's progress in developing therapies that address both chronic neurodegeneration and acute neural injury. Regular updates provide critical insights for stakeholders monitoring advancements in dementia treatment research.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, provided Q2 2025 updates on its clinical progress and financial results. The company's pivotal Phase 3 trial for early Alzheimer's disease has secured 76 U.S. clinical sites, with 38 patients already receiving treatment and approximately 200 more in screening.
Key operational highlights include the appointment of Hui Liu as Director of Biostatistics, successful presentations at AAIC 2025, and the completion of patent family transfers to crystal buntanetap. Financially, Annovis reported cash and equivalents of $17.1 million as of June 30, 2025, with reduced R&D expenses of $5.2 million and G&A expenses of $1.1 million for Q2 2025. The company's net loss per share improved to $0.32 compared to $0.44 in the same quarter last year.
Annovis Bio (NYSE: ANVS) has successfully completed the transfer of all patents to cover both the original semi-crystalline and new crystalline forms of buntanetap, its drug candidate for neurodegenerative diseases. The comprehensive IP portfolio now includes 13 patent families with protection extending to 2046.
The new crystalline form demonstrates improved solid-state stability and comparable pharmacokinetic properties to the original form, with bioequivalence confirmed through animal and human studies. The FDA has already approved the use of the crystalline form in the company's ongoing Phase 3 clinical trial for early Alzheimer's disease, which is currently active with over 75 US sites.
Annovis Bio (NYSE:ANVS) announced its participation in the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto, Canada. The company will present four scientific posters focused on their lead drug candidate, buntanetap, for Alzheimer's disease treatment.
The presentations will cover the Phase III study design for early Alzheimer's patients, details of their 6-month and 18-month pivotal clinical trial, and pharmacokinetic characterization studies of buntanetap in both animals and humans. Senior management team members, including SVP of R&D and other key scientists, will present the research findings at this premier global conference for dementia science.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative disorders, has appointed Hui Liu as Director of Biostatistics. This strategic hire comes as the company advances its pivotal Phase 3 Alzheimer's disease trial.
Ms. Liu brings over 19 years of experience in clinical trial statistics, specializing in:
- Design and analysis of all clinical trial phases
- Statistical methodology expertise
- Development of statistical analysis plans
- Management of high-performing teams
According to Dr. Cheng Fang, Senior VP of Research and Development, Liu's appointment strengthens the company's scientific excellence and will support data integrity for regulatory submissions. The new Director expressed enthusiasm about joining Annovis's team and contributing to their clinical trials' quality evidence generation.
Annovis Bio (NYSE: ANVS) has received a notice from the NYSE on March 26, 2025, indicating non-compliance with continued listing standards. The company's average global market capitalization over 30 trading days fell below $50 million (approximately $37.9 million as of March 25, 2025), while stockholders' equity was $9.3 million as of December 31, 2024.
The company must submit a compliance plan within 45 days, demonstrating its ability to meet NYSE standards within 18 months. During this period, ANVS stock will continue trading with a '.BC' designation. If the plan is accepted, quarterly reviews will ensure compliance. Failure to meet requirements could result in NYSE delisting.
Annovis Bio (NYSE: ANVS) announced its participation in the AD/PD™ 2025 conference taking place April 1-5 in Vienna, where they will present comprehensive data from their latest clinical trials.
The company will deliver two key presentations: one focusing on buntanetap's improvements in cognition and motor functions in Phase 3 Parkinson's disease study, and another examining the drug's advantages for APOE4 carriers in Phase 2/3 Alzheimer's disease trials. Additionally, CEO Maria Maccecchini will participate in a forum discussion about novel approaches to biomarkers, imaging, and therapy development.
The presentations schedule includes:
- April 1, 2:45 PM CET: Buntanetap's impact on early Parkinson's patients
- April 2, 9:40 AM CET: APOE4 and buntanetap in Alzheimer's patients
- April 4, 4:20 PM CET: Forum on novel approaches in PD, LBD and MSA pathologies
Annovis Bio (NYSE: ANVS) reported its Q4 and FY 2024 financial results, highlighting significant clinical progress in their buntanetap program. The company successfully completed two clinical trials - Phase 2/3 Alzheimer's Disease (AD) and Phase 3 Parkinson's Disease (PD), with promising results in improving cognition and motor function.
Financial highlights include:
- Q4 2024 R&D expenses decreased to $5.0M from $8.9M in Q4 2023
- Q4 2024 net loss per share improved to $0.43 from $2.24 year-over-year
- FY 2024 R&D expenses reduced to $20.0M from $38.8M in 2023
- Cash position of $10.6M as of December 31, 2024
- Completed $21.0M stock offering with ThinkEquity
The FDA cleared Annovis to proceed with a pivotal Phase 3 trial in early AD, launched in early 2025. The study includes a 6-month symptomatic data readout expected in mid-2026 and disease-modifying data in mid-2027, both supporting potential New Drug Applications.